ITGAX and neoplasm: Some preclinical studies using mouse tumor models showed that ablative therapies in combination with ICIs significantly increased intratumor infiltration of CD11c+ dendritic cells (DCs), CD4+ T cells, and CD8+ T cells, and decreased the expression of IL-10, resulting in suppressed tumor growth and extended survival of the animals [42,43,44,45,46].